Create Meaningful Metrics for Safety and Quality of Care

Lately, an increased focus on quality and patient safety has evolved, and various healthcare organization have developed metrics specifically related to the care of patients with cancer. However, the increase in quality and safety metrics can be overwhelming.

Spread Awareness on Melanoma Monday

On one of the first warm spring days in St. Louis, I came home and found my active dog, Maggie, sound asleep and enjoying the warmth of the sun. Like many humans, she was taking pleasure in a beautiful day and found it relaxing. As the summer approaches, many will spend much more time outside. Despite the inviting nature of a warm day, there are still hidden dangers.

Susan Schneider

May 2016

ONS Comments on Risk Adjustment Methodology, Attends Future of Health Care Forum, Plans For End-of-Life Roundtable

ONS is working to shape healthcare policies and advocate for oncology nurses everywhere. Find out more about ONS's presence in Washington, DC.

Navigating Moral Distress in the Face of Ethical Dilemmas

Do you remember that moment when you recited the Nightingale Pledge? Although antiquated in language, the modified Hippocratic Oath, written in 1893, still rings true in many ways today. I recall the weightiness of those words. As reiterated in the ANA Code of Ethics for Nurses (2015), nurses are expected to hold those values and ethical principles in the highest regard and should afford them to all people. This is quite a responsibility for even the most seasoned nurse. Moreover, oncology nurses are often faced with issues that test ethical and moral principles.

New Treatment Approach May Be Effective for Aggressive Ovarian Cancer

Approximately 80% of ovarian cancers are classified as a high-grade serous subtype. Because of this, long-term survival rates are usually low. Researchers in a new study have found a treatment approach that may offer promise for this form of ovarian cancer.

FDA Approves Cabozantinib for Renal Cell Cancer

On April 25, 2016, the U.S. Food and Drug Administration approved cabozantinib (Cabometyx®, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy.

FDA Alerts to a Shortage of Bleomycin Sulfate for Injection

The U.S. Food and Drug Administration (FDA) announced in April a shortage of bleomycin sulfate for injection. The shortage affects two dosage sizes (15 and 30 units) and three manufacturers (Fresenius Kabi USA, LLC; Hospira, Inc.; and Teva Pharmaceuticals).

Subscribe to